End-stage renal disease
Conditions
Interventions
Oral pyridoxiamine 300-600 mg
Sponsors
Tokai University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Receiving maintenance peritoneal dialysis at least for 3 months Not reiving vitamin B6 in the last 4 weeks
Exclusion criteria
Exclusion criteria: Receiving hemodialysis in addition to peritoneal dialysis Severe liver disease or liver dysfunction History of allergy or adverse effects to certain drugs Participating in other clinical trials or received investigational products in the last 16 weeks Having active cancers or received complete resection of cancers in the last 3 years History of cardiovascular disease in the last 6 months Receiving peritoneal dialysis for more than 8 years or having suspected encapsulating peritoneal sclerosis Fontaine stage II peripheral arterial disease Treatment resistant hypertension Treatment resistant diabetes Erythropoietin resistant anemia Received aminophylline, theophylline, choline theophylline, or levodopa in the last 4 weeks Pregnant women or those intending to become pregnant during the next 1 year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics of oral pyridoxiamine | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in carbonyl stress in the abdominal cavity and blood | — |
Countries
Japan
Contacts
Public ContactTakatoshi Kakuta
Tokai University School of Medicine Division of Nephrology, Endocrinology and Metabolism
Outcome results
None listed